Elvitegravir cobicistat emtricitabine tenofovir: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Elvitegravir cobicistat emtricitabine tenofovir}} | {{Elvitegravir cobicistat emtricitabine tenofovir}} | ||
'''''For patient information, click <u>[[Elvitegravir cobicistat emtricitabine tenofovir (patient information)|here]]'''''</u>. | '''''For patient information, click <u>[[Elvitegravir cobicistat emtricitabine tenofovir (patient information)|here]]'''''</u>. | ||
{{CMG}}; {{AE}} {{MM}} | {{CMG}}; {{AE}} {{MM}} | ||
Revision as of 06:10, 10 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Category
Antiretroviral
US Brand Names
STRIBILD®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages